National trends in osteoporosis medication use among Medicare beneficiaries with and without Alzheimer’s disease/related dementias
Main finding · OP drug useResult — go to the resultOdds ratio 0.85 95% CI 0.83–0.87Authors' conclusion
ADRD patients received OP drugs at a lower rate than their non-ADRD counterparts.
Study context
- Population
- Medicare beneficiaries with osteoporosis (OP) aged ≥ 67 years with Medicare parts A/B/D without HMO, 2016–2018
- Participants
- 47,871 vs 201,840
- Exposure
- And related dementia (ADRD) vs non-ADRD
- ADRDn = 47,871
- Non-ADRDn = 201,840reference
- Outcome
- Receipt of OP medications
- Follow-up
- 2018
Methodological detailsmultivariable logistic regression, Medicare claims
- Multivariable logistic regression
- Medicare claims
Main finding
OP drug use
Odds ratio
0.85
95% CI 0.83–0.87
By group
ADRDvs non-ADRD
OR 0.85 (95% CI 0.83–0.87)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| OP drug use by ADRD, community-dwelling elders (subgroup)Significant ADRD × NH residency and ADRD × age interactions | 0.88 (0.86–0.90) | |
| OP drug use by ADRD, NH residents (subgroup) | 0.66 (0.64–0.69) | |
| 0.512Odds ratio (log scale) |
OP medication, nursing home (NH) residents (vs non-NH)
- OR for OP medication in NH residents
- 0.61 (95% CI: 0.58-0.64)
Original publication
National trends in osteoporosis medication use among Medicare beneficiaries with and without Alzheimer’s disease/related dementias. Osteoporos Int. Published 2 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →